Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAb11-22.1
- Development stage
- Preclinical
- Lead developer
- MedAbome
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MAb11-22.1 is a monoclonal antibody developed as a therapeutic agent for the treatment, prevention, and diagnosis of cancers associated with cells that overexpress transferrin receptor 1 (TfR1). It has been studied both as a standalone monoclonal antibody and as an antibody-drug conjugate (ADC), where it is linked to cytotoxic payloads to enhance its anti-tumor activity. In vitro assays have shown that MAb11-22.1 exhibits inhibitory effects on the proliferation of cancer cells, particularly those with high TfR1 expression[1][2]. The primary mechanism involves targeting and binding to TfR1 on tumor cells, which may lead to direct inhibition of cell growth or facilitate targeted delivery of cytotoxic agents in ADC formats.
- Other names
- MAb11-22.1MAb-11-22.1MAb 11-22.1
02
Targets
TFRC (Transferrin Receptor)
Beyond the preview
Go deeper on MAb11-22.1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAb11-22.1.